☆ 4.5 Review

Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas

HELIYON (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal et al.

Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Meeting Abstract Oncology

Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations

Yin-Hsun Feng et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements

Mitesh J. Borad et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01

Milind M. Javle et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker-Radtke et al.

Summary: This study evaluated the long-term efficacy and safety of Erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. The results showed consistent activity and manageable safety profile in these patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Andrew J. Weickhardt et al.

Summary: This study identified that FGFR3 fusion genes in bladder cancer cells confer sensitivity to FGFR inhibitors, but resistance is mainly mediated by alternate activation of MAPK signaling. Combination treatment with FGFR and pan-ERBB inhibitors can overcome this resistance.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma

Daniel H. Ahn et al.

Summary: Ponatinib as a single agent in treating BTC with FGFR alterations showed limited clinical activity but was tolerable. The study provides valuable information for the further development of ponatinib in BTC treatment.

INVESTIGATIONAL NEW DRUGS (2022)

添加到收藏夹

Article Oncology

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Funda Meric-Bernstam et al.

Summary: Futibatinib, a selective FGFR1-4 inhibitor, showed clinical activity in various solid tumors, particularly in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma. It also demonstrated efficacy in patients who developed resistance to prior FGFR inhibitors. These findings provide a basis for further clinical trials and highlight the importance of genomic profiling in identifying patients who may benefit from targeted therapy.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Targeting the FGF/FGFR axis and its co-alteration allies

Y. Uehara et al.

Summary: This study analyzed the cancer landscape of FGF/FGFR and co-alterations and found that FGF/FGFR alterations were associated with shorter overall survival. Additionally, FGF/FGFR alterations frequently co-occurred with other pathogenic abnormalities in signaling pathways. In terms of treatment, co-targeting both the cyclin and FGFR pathways with CDK4/6 and FGFR inhibitors showed promising results.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma

Jennifer J. Gile et al.

Summary: This study describes the clinical outcomes of patients with cholangiocarcinoma harboring FGFR alterations following initial FGFR inhibitor treatment. The study found that although initial FGFR inhibitor therapy prolonged progression-free survival, most patients still required subsequent systemic therapy after discontinuing FGFR inhibitor treatment. Understanding the mechanisms of resistance to FGFR inhibitors is crucial for guiding treatment sequencing.

TARGETED ONCOLOGY (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants

Qianmeng Lin et al.

Summary: This study analyzed the biochemical and structural characteristics of pemigatinib as a FGFR inhibitor for the treatment of cholangiocarcinoma. It was found that pemigatinib is a potent and selective inhibitor of FGFR1-3, with excellent potency against specific mutations.

COMMUNICATIONS CHEMISTRY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Futibatinib: First Approval

Yahiya Y. Syed

Summary: Futibatinib is an oral drug that inhibits FGFR1-4 and is used for the treatment of various cancers. It has been approved in the USA for the treatment of cholangiocarcinoma.

DRUGS (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo

Meng-di Dai et al.

Summary: DW14383 is a promising selective irreversible pan-FGFR inhibitor with pan-tumor spectrum potential in FGFR1-4 aberrant cancers, which has the potential to overcome compensatory activation among FGFR1-4.

ACTA PHARMACOLOGICA SINICA (2021)

添加到收藏夹

Review Oncology

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

Melanie A. Krook et al.

Summary: FGFRs are aberrantly activated in 5-10% of human cancers through genetic alterations, with FGFR-targeted therapies showing significant advancements in the past decade. However, acquired drug resistance leading to cancer progression remains a challenge in most patients.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Article Cell Biology

Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas

Xiaohong Pu et al.

Summary: Chromosomal translocations involving FGFR2 are common in ICC, with sensitivity to FGFR kinase inhibitors being crucial for prognosis. FGFR2 fusions can be classified into three subtypes, with classical and sub-classical fusions showing sensitivity to inhibitors, highlighting the importance of determining the type of FGFR2 fusions in ICC for targeted treatment.

CELL DEATH & DISEASE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle et al.

Lancet Gastroenterology & Hepatology (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Infigratinib: First Approval

Connie Kang

Summary: Infigratinib, a FGFR-specific tyrosine kinase inhibitor, has been approved in the USA for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with specific genetic abnormalities.

DRUGS (2021)

添加到收藏夹

Article Oncology

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma

Michael Bitzer et al.

Summary: In this study, two iCCA patients with extracellular and juxtamembrane FGFR2 mutations were treated with an FGFR-inhibiting tyrosine kinase inhibitor under the guidance of MTB, leading to rapid and prolonged partial response. This suggests the importance of predicting the functional consequences of FGFR2 mutations for guiding treatment decisions in iCCA patients.

NPJ PRECISION ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer

Ikuko Takeda Nakamura et al.

Summary: This study evaluated the transforming activity and sensitivity of various FGFR mutations and fusion genes to FGFR TKIs, discovering new oncogenic mutations and revealing the impact of recurrent compound mutations. It suggests the importance of selecting suitable inhibitors against individual FGFR variants and the necessity of developing next-generation FGFR inhibitors effective against all oncogenic FGFR variants.

NPJ PRECISION ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Metastatic Urothelial Cancer: a rapidly changing treatment landscape

Carlos Stecca et al.

Summary: Metastatic urothelial cancer remains incurable with limited life expectancy, but recent therapeutic advances such as immunotherapy and targeted agents have shown promising results.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

添加到收藏夹

Review Chemistry, Medicinal

Recent advance in the development of novel, selective and potent FGFR inhibitors

Feng-Tao Liu et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder

Robert Roskoski

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Article Oncology

Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results

Sumanta K. Pal et al.

CANCER (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Pemigatinib: First Approval

Sheridan M. Hoy

DRUGS (2020)

添加到收藏夹

Article Oncology

FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

Lipika Goyal et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Phillip C. C. Liu et al.

PLOS ONE (2020)

添加到收藏夹

Article Oncology

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou-Alfa et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Tanios S. Bekaii-Saab et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial

Shalini Makawita et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome et al.

CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

Rastislav Bahleda et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma

Lipika Goyal et al.

CANCER DISCOVERY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Erdafitinib: First Global Approval

Anthony Markham

DRUGS (2019)

添加到收藏夹

Article Medicine, General & Internal

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Y. Loriot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Cell Biology

Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

Shuyan Dai et al.

CELLS (2019)

添加到收藏夹

Article Oncology

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Vincenzo Mazzaferro et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Review Oncology

Fibroblast growth factor receptors as treatment targets in clinical oncology

Masaru Katoh

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

Sumanta K. Pal et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Oncology

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

Noah M. Hahn et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

Lipika Goyal et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

Lucia Nogova et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

K. P. Papadopoulos et al.

BRITISH JOURNAL OF CANCER (2017)

添加到收藏夹

Review Oncology

Advances and challenges in targeting FGFR signalling in cancer

Irina S. Babina et al.

NATURE REVIEWS CANCER (2017)

添加到收藏夹

Article Oncology

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

J. Wang et al.

ONCOGENE (2015)

添加到收藏夹

Article Oncology

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

Matthew I. Milowsky et al.

EUROPEAN JOURNAL OF CANCER (2014)

添加到收藏夹

Review Biochemistry & Molecular Biology

Cellular signaling by fibroblast growth factor receptors

VP Eswarakumar et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.